Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection.
COVID-19
CpG ODN Adjuvant
SARS-CoV-2
vaccine
virus-like particle
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
02
08
2021
received:
11
07
2021
accepted:
15
08
2021
pubmed:
15
9
2021
medline:
5
1
2022
entrez:
14
9
2021
Statut:
ppublish
Résumé
Vaccines that incorporate multiple SARS-CoV-2 antigens can further broaden the breadth of virus-specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS-CoV-2 VLP vaccine that incorporates the four structural proteins of SARS-CoV-2. VLPs were generated in transiently transfected HEK293 cells, purified by multimodal chromatography, and characterized by tunable-resistive pulse sensing, AFM, SEM, and TEM. Immunoblotting studies verified the protein identities of VLPs. Cellular and humoral immune responses of immunized animals demonstrated the immune potency of the formulated VLP vaccine. Transiently transfected HEK293 cells reproducibly generated vesicular VLPs that were similar in size to and expressing all four structural proteins of SARS-CoV-2. Alum adsorbed, K3-CpG ODN-adjuvanted VLPs elicited high titer anti-S, anti-RBD, anti-N IgG, triggered multifunctional Th1-biased T-cell responses, reduced virus load, and prevented lung pathology upon live virus challenge in vaccinated animals. These data suggest that VLPs expressing all four structural protein antigens of SARS-CoV-2 are immunogenic and can protect animals from developing COVID-19 infection following vaccination.
Sections du résumé
BACKGROUND
Vaccines that incorporate multiple SARS-CoV-2 antigens can further broaden the breadth of virus-specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS-CoV-2 VLP vaccine that incorporates the four structural proteins of SARS-CoV-2.
METHODS
VLPs were generated in transiently transfected HEK293 cells, purified by multimodal chromatography, and characterized by tunable-resistive pulse sensing, AFM, SEM, and TEM. Immunoblotting studies verified the protein identities of VLPs. Cellular and humoral immune responses of immunized animals demonstrated the immune potency of the formulated VLP vaccine.
RESULTS
Transiently transfected HEK293 cells reproducibly generated vesicular VLPs that were similar in size to and expressing all four structural proteins of SARS-CoV-2. Alum adsorbed, K3-CpG ODN-adjuvanted VLPs elicited high titer anti-S, anti-RBD, anti-N IgG, triggered multifunctional Th1-biased T-cell responses, reduced virus load, and prevented lung pathology upon live virus challenge in vaccinated animals.
CONCLUSION
These data suggest that VLPs expressing all four structural protein antigens of SARS-CoV-2 are immunogenic and can protect animals from developing COVID-19 infection following vaccination.
Identifiants
pubmed: 34519053
doi: 10.1111/all.15091
pmc: PMC8653174
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Vaccines, Virus-Like Particle
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
258-270Subventions
Organisme : Turkish Scientific and Research Council
Informations de copyright
© 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Nat Med. 2021 Aug;27(8):1379-1384
pubmed: 34127854
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Hum Vaccin. 2008 May-Jun;4(3):246-50
pubmed: 18382138
J Virol. 2007 Apr;81(7):3487-94
pubmed: 17202212
Vaccine. 2014 Nov 12;32(48):6377-89
pubmed: 24975812
Am J Epidemiol. 1969 Apr;89(4):422-34
pubmed: 4305198
PLoS Pathog. 2021 Dec 2;17(12):e1010022
pubmed: 34855916
Allergy. 2022 Jan;77(1):258-270
pubmed: 34519053
Nature. 2020 Dec;588(7838):498-502
pubmed: 32805734
Vaccine. 2020 Oct 27;38(46):7246-7257
pubmed: 33012605
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Virology. 2006 Sep 1;352(2):418-26
pubmed: 16777168
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Science. 2021 Aug 6;373(6555):648-654
pubmed: 34210893
EMBO J. 2021 Mar 1;40(5):e106228
pubmed: 33258165
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Am J Respir Cell Mol Biol. 2011 May;44(5):725-38
pubmed: 21531958
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Adv Drug Deliv Rev. 2009 Mar 28;61(3):248-55
pubmed: 19272313
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Am J Respir Cell Mol Biol. 2021 Jan;64(1):79-88
pubmed: 32991819
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
J Virol. 2011 Dec;85(23):12201-15
pubmed: 21937658
FEMS Immunol Med Microbiol. 2001 Dec;32(1):65-71
pubmed: 11750224
J Immunol. 2021 Jul 15;207(2):376-379
pubmed: 34193597
NPJ Vaccines. 2021 May 13;6(1):71
pubmed: 33986292
Science. 2020 Sep 25;369(6511):1603-1607
pubmed: 32732280
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Vaccine. 2005 Mar 18;23(17-18):2273-9
pubmed: 15755610
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Cell. 2021 Aug 5;184(16):4220-4236.e13
pubmed: 34242578
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Vet Immunol Immunopathol. 2006 Nov 15;114(1-2):103-10
pubmed: 16950519
Lancet. 2021 Apr 10;397(10282):1351-1362
pubmed: 33798499
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Nat Commun. 2021 Jan 14;12(1):372
pubmed: 33446655
Expert Rev Vaccines. 2014 Feb;13(2):299-312
pubmed: 24308579
Clin Vaccine Immunol. 2006 Sep;13(9):981-90
pubmed: 16960108
J Immunol. 2008 Sep 15;181(6):4168-76
pubmed: 18768874
J Immunol. 2001 Jun 15;166(12):7381-8
pubmed: 11390489